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ndothelial Dysfunction After
irolimus-Eluting Stent Placement*
od Serry, MD,
illiam F. Penny, MD, FACC
an Diego, California
n this issue of the Journal, Togni et al. (1) report that
xercise-induced coronary vasomotion is abnormal in seg-
ents proximal and distal to sirolimus-eluting stents (SES)
hen evaluated six months after deployment. While sub-
ects who had received bare-metal stents demonstrated
ormal exercise-induced vasodilation, subjects with SES
learly demonstrated paradoxical vasoconstriction in peri-
tent segments, although the vasodilator response to nitro-
lycerin was maintained.
See page 231
The normal response to increased flow in coronary
onductance vessels is vasodilation, which is due to stimu-
ation of endothelial nitric oxide (NO) synthesis and release
2,3) in response to shear stress. During exercise, areas of
he coronary arteries with damaged endothelium or abnor-
al endothelial function fail to exert this NO response onto
he vascular smooth muscle. Subsequently, normal vasodi-
ation fails to occur and can be replaced by paradoxical
asoconstriction, possibly attributable to the effect of circu-
ating catecholamines (4).
Abnormal endothelial responses have been demonstrated
arly after balloon percutaneous transluminal coronary an-
ioplasty but are normalized at follow-up months later
5,6). Evaluation of endothelial function within coronary
tents has not been possible with current catheterization-
ased techniques because they rely on the assessment of
asomotion, which is prevented by the stent apparatus.
owever, coronary segments on the edges of bare-metal
tents have been shown to demonstrate a normal vasodilator
esponse to exercise when evaluated at 4 to 8 months after
tent deployment in this current work and at 7 to 13 months
fter stent deployment in a previous publication by Maier et
l. (7).
The evidence of peri-stent endothelial dysfunction after
ES is in sharp contrast to its consistent absence after
are-metal stenting in this study, but the mechanism by
hich this abnormality is conferred remains unclear. The
ypher stents (Cordis Corp., Miami Lakes, Florida) used
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.(
From the University of California, San Diego/VA Medical Center, San Diego,
alifornia.ere contain a 5-m thick coating of the drug sirolimus
ixed with non-erodable polymers, topped with a layer of
rug-free polymer to allow the release of approximately 80%
f the drug within 30 days after implantation (8). Sirolimus
rapamycin) is a macrolide antibiotic that binds to its
ytosolic receptor, FKBP12, and inhibits down-regulation
f the cyclin-dependent kinase inhibitor p27kip1, blocking
ransition from G1 to S phase in the cell cycle (9) and
nhibiting vascular smooth muscle cell proliferation and
igration.
Rapamycin has been shown to impair endothelium-
ependent relaxation in an in vitro model using porcine
picardial coronary arteries (10), but it has not been estab-
ished that this is of consequence with clinical use of SES.
ecause most of the drug sirolimus is eluted from the
olymer coating the stent by 28 days (11) and is reportedly
ully eluted by 60 days (12), the abnormal vasomotion
bserved at six months in the current study should not be
he result of a direct effect of sirolimus itself. However, the
nduction of a persistent abnormality in intact or regener-
ting endothelium occurring while sirolimus was present
annot be excluded. Alternatively, the polymer from which
he drug elutes, which may have contributed to a case of a
arked hypersensitivity reaction (12), could be involved in
he abnormal vasomotion observed, but this also remains
peculative.
As the authors note, the finding of paradoxical constric-
ion could be the result of delayed endothelialization, with
nadequate endothelial coverage leading to insufficient NO
elease to promote normal vasodilation with exercise. Al-
hough this could explain the finding of endothelial dys-
unction within the stent and at the immediate edges, the
ngiograms in Figure 1 of the paper (1) show vasoconstric-
ion well beyond the distal margin of the stent. Although
he authors did not specify their deployment technique and
se of predilation, none of the subjects in the current study
ad evidence of restenosis, and it seems unlikely that this
ysfunctional distal segment (as much as 10 mm distal to
he stent) had been subject to balloon dilation and de-
ndothelialization during stent placement. As noted previ-
usly, diffusion of sirolimus well beyond the stent margins
ith induction of a sustained functional impairment of
ontraumatized endothelium may play a role in this finding.
ogni et al. (13) also have recently reported a similar
bservation of abnormal peri-stent vasomotor responsive-
ess in subjects studied 8 to 10 months after brachytherapy
or in-stent restenosis. As in the present study, it is not clear
hat the abnormal segments were de-endothelialized via
alloon trauma, but the beta radiation was applied well
eyond the stent margins, raising the possibility of a
unctional incapacitation of intact endothelium.
Concerns that drug-eluting stents (DES) may be associ-
ted with increased risk of subacute and later thrombosis
ave not been substantiated by clinical trial and registry data
14,15) and the U.S. Food and Drug Administration has
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Editorial Comment July 19, 2005:237–8ontinued to regard these therapies as safe (16), but case
eports have described DES thrombosis occurring beyond
ne year after deployment (17). Although the number of
uch patients appears to be small based on current data, the
bility to identify specific factors placing a patient at greater
isk of thrombosis after DES or to identify those patients
ho may need extended antiplatelet therapy without inter-
uption would be of great value. Whether evidence of
ersistent peri-SES endothelial dysfunction will be a risk
actor for adverse late events, however, will require further
tudy. While the occurrence of late stent thrombosis re-
ains low, the authors have demonstrated that endothelial
ysfunction occurs in the majority of patients after SES
lacement, suggesting it may not be a finding specifically
ortending adverse outcomes. In fact, the subjects chosen
or this current study were included because of an unevent-
ul six-month poststent clinical course and no evidence of
estenosis.
The many questions raised by this work underscore the
eed for additional investigation. Further insight into the
echanism by which paradoxical constriction is associated
ith SES placement is required, and the duration of this
bnormal vasomotor response remains to be defined.
hether endothelial dysfunction in this setting will ad-
ersely affect prognosis, as has been shown in other clinical
ontexts (18), and the effects of approaches manipulating
ndothelial response (19) are to be determined. Character-
zation of coronary vasomotion after the use of paclitaxel-
luting stents also is needed. Future studies in this area will
elp clarify the clinical implications of this stimulating
eminal observation of endothelial dysfunction after DES
lacement.
eprint requests and correspondence: Dr. William F. Penny,
niversity of California, San Diego/VA Medical Center, 3350 La
olla Village Drive (111A), San Diego, California 92161. E-mail:
penny@ucsd.edu.
EFERENCES
1. Togni M, Windecker A, Cocchia R, et al. Sirolimus-eluting stents
associated with paradoxic coronary vasoconstriction. J Am Coll Car-
diol 2005;46:231–6.2. Cooke JP, Rossitch E Jr., Andon NA, Loscalzo J, Dzau VJ. Flow
activates an endothelial potassium channel to release an endogenous
nitrovasodilator. J Clin Invest 1991;88:1663–71.
3. Nadaud S, Philippe M, Arnal JF, et al. Sustained increase in aortic
endothelial nitric oxide synthase expression in vivo in a model of
chronic high blood flow. Circ Res 1996;79:857–63.
4. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the
vasomotor response of epicardial coronary arteries to exercise. J Clin
Invest 1989;83:1946–52.
5. Lazzam C, Forster C, Gotlieb A, Dawood F, Schwartz L, Liu P.
Impaired vascular reactivity following angioplasty is mainly due to
endothelial injury. Exp Mol Pathol 1992;56:153–62.
6. Suter TM, Hess OM, Bortone A, Nonogi H, Grimm J, Krayenbuehl
HP. Coronary stenosis vasomotion during dynamic exercise before and
after PTCA. Eur Heart J 1989;10 Suppl G:58–63.
7. Maier W, Windecker S, Küng A, et al. Exercise-induced coronary
artery vasodilation is not impaired by stent placement. Circulation
2002;105:2373–7.
8. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison
of a sirolimus eluting stent with a standard stent for coronary
revascularization. N Engl J Med 2002;346:1773–80.
9. Marx SO, Marks AR. Bench to bedside: the development of rapamy-
cin and its application to stent restenosis. Circulation 2001;104:852–5.
0. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault
LP. Comparative study of cyclosporine and tacrolimus vs newer
immunosuppressants mycophenolate mofetil and rapamycin on coro-
nary endothelial function. J Heart Lung Transplant 2002;21:990–8.
1. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy
and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis
2002;13:183–8.
2. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and
late coronary thrombosis secondary to a sirolimus-eluting stent should
we be cautious? Circulation 2004;109:701–5.
3. Togni M, Windecker S, Wenaweser P, et al. Deleterious effect of
coronary brachytherapy on vasomotor response to exercise. Circulation
2004;110:135–40.
4. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful
sirolimus-eluting stent implantation. Circulation 2004;109:1930–2.
5. Holmes DR Jr., Leon MB, Moses JW, et al. Analysis of 1-year clinical
outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting
stent versus a standard stent in patients at high risk for coronary
restenosis. Circulation 2004;109:634–40.
6. Muni NI, Gross TP. Problems with drug-eluting coronary stents—the
FDA perspective. N Engl J Med 2004;351;1593–5.
7. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in
drug-eluting coronary stents after discontinuation of antiplatelet ther-
apy. Lancet 2004;364:1519–21.
8. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr.,
Lerman A. Long-term follow-up of patients with mild coronary artery
disease and endothelial dysfunction. Circulation 2000;101:948–54.
9. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium
in modulating neointimal formation: vasculoprotective approaches to
attenuate restenosis after percutaneous coronary interventions. J Am
Coll Cardiol 2004;44:733–9.
